Raylumis
Country: European Union
Language: Bulgarian
Source: EMA (European Medicines Agency)
Public Assessment Report
(PAR)
01-01-1970
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
Tanezumab
Available from:
Pfizer Europe MA EEIG
ATC code:
N02
INN (International Name):
tanezumab
Therapeutic group:
Аналгетици
Therapeutic area:
Osteoarthritis; Pain
Therapeutic indications:
Treatment of moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or any opioid is ineffective, not tolerated or inappropriate.
Authorization status:
Отказана
